UK markets closed

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
485.00-16.00 (-3.19%)
At close: 05:11PM BST

Oxford BioMedica plc

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000
https://www.oxb.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees805

Key executives

NameTitlePayExercisedYear born
Dr. Roch DoliveuxInterim CEO & Chairman225kN/AN/A
Mr. Stuart PaynterCFO, Company Sec. & Director755kN/A1974
Mr. Nick PageChief Operations OfficerN/AN/AN/A
Dr. James Miskin Ph.D.Chief Technical OfficerN/AN/AN/A
Dr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Matthew TreagusChief Information OfficerN/AN/AN/A
Sophia BolhassanHead of Investor RelationsN/AN/AN/A
Ms. Natalie Louise WalterGen. CounselN/AN/AN/A
Dr. Jason Slingsby MBAChief Bus. & Corp. Devel. OfficerN/AN/AN/A
Ms. Sarah MacleodHead of CommunicationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Oxford BioMedica plc’s ISS governance QualityScore as of 31 July 2022 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.